Q1 2023 Results

Company overview Financial review Conclusions Appendix References Continuing core margin improvements for Group driven by IM FINANCIAL PROFILE Q1 2023 Net sales change vs. PY1 Core operating income % CC change vs. PY1 % CC Core margin¹ Core margin change vs. PY1 % %pts cc Innovative Medicines 7 18 38.7 3.6 Sandoz Group 8 3 21.1 -1.0 8 15 34.1 2.2 1. Constant currencies (cc), core results are non-IFRS measures. An explanation of non-IFRS measures can be found on page 35 of the Condensed Interim Financial Report. 23 Investor Relations | Q1 2023 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation